Exelixis | EXEL - 销售收入



金融业
股票价格
USD
资产
USD 2.59B
现金及等价物
USD 226.15M
销售成本
USD 19.95M
流动资产
USD 1.21B
流动负债
USD 370.98M
债务
USD 169.54M
EBIT
USD 251.34M
EBITDA
USD 258.29M
员工
1.15K
EPS每股收益
USD 0.87
股本和储备
USD 1.94B
销售毛利
USD 590.86M
债务利息支出
USD 23.4M
利息收入
USD 16.13M
市值
USD 14.28B
净收入
USD 210.47M
营业费用
USD 359.47M
营业利润
USD 251.34M
普通股股本
USD 253.7M
PE价格收益
13.91
税前利润
USD 267.69M
销售收入
USD 610.8M
销售和管理费用
USD 139.6M
股票
USD 26.61M
贸易债权人
USD 24.15M
应收帐款人
USD 328.95M


销售 更改 日
Acadia Pharmaceuticals USD 268.06M 15.94M 2026-03
Agios Pharmaceuticals USD 18.8M 1.17M 2026-03
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Amgen USD 8.62B 1.28B 2026-03
AstraZeneca USD 15.29B 213M 2026-03
Bayer EUR 13.41B 1.97B 2026-03
BioMarin Pharmaceutical USD 766M 109M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
Cytokinetics USD 19.35M 1.59M 2026-03
Eisai JPY 205.43B 14.51B 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Exelixis USD 610.8M 12.14M 2026-03
Genmab DKK 1.06B 36M 2025-12
Glaxosmithkline GBP 10.09B 1.37B 2026-03
Incyte USD 1.27B 240M 2026-03
Ionis Pharmaceuticals USD 246M 43M 2026-03
MacroGenics USD 20.8M 20.43M 2026-03
Merck USD 16.29B 110M 2026-03
Moderna USD 389M 289M 2026-03
Nektar Therapeutics USD 21.81M 2.32M 2025-12
Neurocrine Biosciences USD 811M 5.5M 2026-03
Novartis USD 13.11B 226M 2026-03
Pfizer USD 14.5B 3.08B 2026-03
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sanofi EUR 12.14B 65M 2026-03
Takeda JPY 1.09T 100B 2026-03
Ultragenyx Pharmaceutical USD 136M 71M 2026-03
Xencor USD 4.51M 23.73M 2026-03